We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.44 | 1.58% | 28.25 | 28.325 | 27.94 | 27.94 | 59,892,143 | 00:42:34 |
From May 2021 to May 2024
By Colin Kellaher
Pfizer Inc. on Wednesday said a Phase 2b/3 study of oral, once-daily ritlecitinib met its main endpoint in patients with alopecia areata, an autoimmune disease that causes hair loss on the scalp and can also affect the face and body.
The New York drugmaker said ritlecitinib achieved the primary efficacy endpoint of the proportion of patients with scalp hair loss of 20% or less after six months of treatment versus placebo.
Pfizer said the data, along with results from an ongoing long-term study, will form the basis for planned future regulatory filings, adding that there are currently no approved treatments in the U.S. or Europe for alopecia areata.
Pfizer is also studying ritlecitinib for vitiligo, rheumatoid arthritis, Crohn's disease and ulcerative colitis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 04, 2021 07:39 ET (11:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
